For patients with pancreatic cancer combined with liver metastasis, chemotherapy and supportive therapy are usually recommended to improve patients’ quality of life. Pancreatic cancer is a malignant tumor of the digestive tract with insidious onset, rapid progression, and extremely poor therapeutic efficacy and prognosis. Patients with pancreatic cancer combined with liver metastasis have a poor prognosis, and the median survival is often less than 6 months. For patients with pancreatic cancer combined with liver metastasis, chemotherapy is often preferred: patients with better physical ability can choose FOLFIRINOX, gemcitabine combined with albumin combined with paclitaxel or gemcitabine combined with tiglium, etc.; those with poor physical status can choose gemcitabine or tiglium single-agent regimen. Gemcitabine combined with molecular targeted therapy is also a feasible choice. For some patients, surgical treatment and interventional therapy can be combined to control the metastases. In addition, patients should be given supportive treatment, such as severe pain, can follow the doctor’s advice to take opioids; for jaundice, liver preservation treatment and drainage surgery, commonly used drugs such as reduced glutathione. If pancreatic cancer is suspected or diagnosed, it is recommended to go to a regular hospital to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate program according to the situation to avoid delaying the condition.